Previous Close | 0.0400 |
Open | 0.0300 |
Bid | 0.0000 |
Ask | 1.3000 |
Strike | 27.50 |
Expire Date | 2025-01-17 |
Day's Range | 0.0300 - 0.0400 |
Contract Range | N/A |
Volume | |
Open Interest | 89 |
WILMINGTON, Del., April 16, 2024--Updated exploratory results from the TOPAZ-1 Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care chemotherapy demonstrated a clinically meaningful long-term overall survival (OS) benefit at three years for patients with advanced biliary tract cancer (BTC).
The FDA approves AstraZeneca's (AZN) Fasenra as an add-on maintenance treatment for patients with severe asthma aged six to 11 years.
J&J (JNJ) is set to buy Shockwave Medical (SWAV). FDA approves AstraZeneca's (AZN) Enhertu for metastatic HER2-positive solid tumors.